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The CD1 molecules are a cluster of nonpoly-
morphic, MHC class I–like glycoproteins that 
present lipid-based antigens to αβ T cells (1, 2). 
They comprise group I, CD1a, CD1b, CD1c, 
and CD1e molecules found in humans and 
the group II CD1d molecule that is expressed 
in humans, mice, and rats (1, 2). CD1d binds 
both self and foreign glycolipids (3–11), includ-
ing the glycosphingolipid α-galactosylceramide 
(α-GalCer) (3), an archetypal CD1d ligand that 
binds well to both human (hCD1d) and mouse 
CD1d (mCD1d) molecules and is a potent ag-
onist for NKT cells (6, 12, 13). Recently, the 
structure of α-GalCer complexed with hCD1d 
and mCD1d was determined (14, 15), reveal-
ing that the acyl and sphingosine lipid chains 
of α-GalCer are buried in the antigen (Ag)-
binding cavity, whereas the polar glycosyl head 
group protrudes from the CD1d cleft, where it 
is available for TCR interaction.
In contrast with polyclonal T cell recog-
nition of the group I CD1 molecules (16), T 
cell recognition of CD1d–glycolipid complexes 
preferentially selects a semi-invariant TCR with 
a fi  xed α-chain and restricted β-chain, exclu-
sively expressed by a subset of T cells known as 
NKT cells (17–19). The human invariant NKT 
cell TCR α-chain uses a Vα24-Jα18 (TRAV10-
TRAJ18) (20) rearrangement that encodes a 
germline-encoded junctional sequence with a 
single codon deletion at the Vα−Jα junction, 
preserving amino acid sequence identity among 
human NKT TCR α-chains (12, 17–19). NKT 
cells are also present in other mammalian spe-
cies, including mice that express a homologous 
invariant Vα14-Jα18 (TRAV11-J15) TCR 
α-chain rearrangement (20). Most human 
NKT cells express Vβ11 (TRBV25-1) (20) 
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Little is known regarding the basis for selection of the semi-invariant 𝗂𝗃 T cell receptor 
(TCR) expressed by natural killer T (NKT) cells or how this mediates recognition of CD1d–
glycolipid complexes. We have determined the structures of two human NKT TCRs that 
differ in their CDR3𝗃 composition and length. Both TCRs contain a conserved, positively 
charged pocket at the ligand interface that is lined by residues from the invariant TCR  
𝗂- and semi-invariant 𝗃-chains. The cavity is centrally located and ideally suited to inter-
act with the exposed glycosyl head group of glycolipid antigens. Sequences common to 
mouse and human invariant NKT TCRs reveal a contiguous conserved “hot spot” that provides 
a basis for the reactivity of NKT cells across species. Structural and functional data suggest 
that the CDR3𝗃 loop provides a plasticity mechanism that accommodates recognition of a 
variety of glycolipid antigens presented by CD1d. We propose a model of NKT TCR–CD1d–
glycolipid interaction in which the invariant CDR3𝗂 loop is predicted to play a major role in 
determining the inherent bias toward CD1d. The fi  ndings defi  ne a structural basis for the 
selection of the semi-invariant 𝗂𝗃 TCR and the unique antigen specifi  city of NKT cells.
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rearranged to form variable Dβ−Jβ combinations (17–19), 
whereas mouse NKT cells typically use either Vβ8.2, Vβ2, or 
Vβ7 (TRBV13-2, BV1, or BV29, respectively) (13, 20–22). 
The crucial role played by the NKT TCR α-chain is high-
lighted by the lack of NKT cells in TCR Jα18 gene-targeted 
mice (23).   Alternatively, the role of Vβ in NKT cell selection 
and Ag recognition appears to be more subtle. For example, 
mouse NKT cells expressing Vβ8.2 display higher affi   nity 
binding toward IgG1-CD1d/αGalCer dimers than NKT 
cells expressing Vβ7 (24). These data have been interpreted 
to mean that complementarity-determining region (CDR)1β 
and CDR2β may be more important than CDR3β in NKT 
specifi  city (24), perhaps by mediating contacts with CD1d. 
This view is consistent with the high degree of natural vari-
ability in CDR3β sequences in NKT cells (25–27) and the 
comparable affi   nity of hybrid NKT TCRs substituted with 
noncognate mouse Vβ8.2 chains derived from conventional 
αβ T cells (28). However, the role of CDR3β in NKT cell 
specifi  city is controversial (25) in that some studies of mouse 
NKT hybridomas and CD1d mutants implicate CDR3β in 
the fi  ne specifi  city of NKT Ag recognition (24, 29–31), in-
cluding the suggestion of a novel CDR3β motif in human 
NKT cells expanded with α-GalCer (12). Remarkably, hu-
man NKT cells can also recognize mouse CD1d–α-GalCer 
complexes (32) and vice versa, indicating the evolutionary 
importance of NKT cells in immunity (33).
The structural explanation for selection of the semi-
  invariant NKT TCR, the role of the CDR3β loops in NKT 
specifi  city, and the basis for the reciprocal cross-species reac-
tivity in Ag recognition by human and mouse NKT cells re-
main unresolved. Here, we describe the structure of two 
diff  erent semi-invariant TCRs, NKT12 and NKT15, from 
human NKT cells. The fi  ndings defi  ne a structural basis for 
the extreme αβ selection of NKT cell TCRs and indicate a 
mechanism for how the conformation and plasticity of the 
CDR3β loops could modulate binding of diff  erent CD1d-
glycolipid antigens. A proposed model of the NKT TCR–α-
GalCer complex provides new insights into Ag recognition 
and cross-species reactivity by NKT TCRs.
RESULTS
The semi-invariant T cell receptors
NKT cells were expanded from PBMCs by stimulation 
with α-GalCer, and cDNA corresponding to the TCRα 
and β gene transcripts was isolated. Three NKT receptors 
(NKT12, NKT15, and NKT18) were characterized as con-
taining the invariant Vα24-Jα18 (TRAV10-TRAJ18) (20). 
NKT12 and NKT15 had Vβ11 (TRBV25-1) (20) rear-
ranged to Dβ segment ΤRBD1 and Jβ segment TRBJ2-7 
(20), whereas NKT18 Vβ11 was rearranged to Dβ ΤRBD1 
and Jβ TRBJ2-1 (20). All three receptors diff  ered in the 
Figure 1.  Structural and functional integrity of recombinant soluble 
NKT TCRs. (A) Purifi  ed bacterial NKT15 TCR was analyzed by SDS-PAGE 
under reducing (+DTT, dithiothreitol) and nonreducing (−DTT) conditions 
demonstrating αβ heterodimers. (B) Native gel electrophoresis of folded 
αβ heterodimeric NKT15 and control LC13 TCRs. (C) Recombinant soluble 
NKT12, NKT15, NKT18, and control LC13 TCRs were tested for their ability 
to block binding of mouse CD1d/α-GalCer tetramers to murine thymo-
cytes. Phycoerythrin-conjugated mCD1d/α-GalCer tetramers were prein-
cubated with the indicated soluble TCRs over a range of TCR 
concentrations before staining mouse thymocytes. Cells were analyzed by 
two-color fl  ow cytometry showing mCD1d/α-GalCer tetramer staining on 
the vertical axis and FITC-CD3 (mAb 145-2C11) staining on the horizontal 
axis. Cells staining positively with mCD1d/α-GalCer tetramer and FITC-CD3 
are indicated with a circle.
Table I. Amino acid sequences of CDR3β residues in NKT TCRs
TCR Gene segment
V𝗃 D𝗃 + NJ 𝗃
NKT12 92CAS94 95TSRRG99 100SY105E  Q  Y  F  G  P  G  T  R  L  T  V  T  117
NKT15 92CASS95 96GLRDRGL102 103Y105E  Q  Y  F  G  P  G  T  R  L  T  V  T  117
NKT18 92CASS95 96APGTGD101 102N105E  Q  F  F  G  P  G  T  R  L  T  V  L  117
LC13 92CASS95 96LGQA99 100Y105E  Q  Y  F  G  P  G  T  R  L  T  V  T  117JEM VOL. 203, March 20, 2006  663
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length and composition of their CDR3β loops (Table I). ± 
Thus, the CDR3β of NKT15 is two residues longer than 
NKT12 and one residue longer than NKT18. The extra-
cellular domains of the NKT12, NKT15, and NKT18 
TCRs were expressed in Escherichia coli, then folded into a 
native conformation and purifi  ed by multiple rounds of 
chromatography as described in Materials and methods. 
The quality and function of the recovered protein was as-
sessed by gel fi  ltration size exclusion chromatography, ELISA 
reactivity with the conformation-dependent mAb 12H8 
(anti-Cα/Cβ) (34) (not depicted), SDS-PAGE (Fig. 1 A), 
and native gel electrophoresis (Fig. 1 B). [ID]FIG1[/ID] To further   confi  rm 
that the complexes were in a natural conformation, they 
were tested for their ability to block binding of mouse 
CD1d/α-GalCer tetramers to mouse NKT cells. The assay 
confi  rmed that the soluble receptors retained their original 
antigen reactivity over a comparable dose range (Fig. 1 C). 
The NKT18 TCR was used for binding studies only, 
whereas the structures of the NKT12 and NKT15 TCRs 
were determined. The NKT12 and NKT15 TCRs were 
crystallized in an orthorhombic space group and their struc-
tures were determined to 2.4Å and 2.2Å resolution, respec-
tively. In addition, the NKT15 TCR also crystallized in a 
trigonal space group, and this crystal form was determined 
to 2.6 Å resolution. The collection statistics and refi  nement 
data are shown in Table II. ±
Table II. Data collection and refi  nement statistics
NKT12
Orthorhombic
NKT15
Orthorhombic
NKT15
Trigonal
Data collection
  Temperature 100 K 100 K 100 K
 Space  group C2221 C2221 P32
  Cell dimensions (Å) (a,b,c) 58.92, 131.39, 117.80 59.84, 131.03, 116.85 66.67, 66.67, 182.41
 Resolution  (Å) 2.4 2.2 2.6
  Total no. observations 65,216 79,368 77,333
  No. unique observations 18,076 22,974 27619
 Multiplicity  3.60 3.45 2.80
  Data completeness (%) 98.7 (96.8) 97.5 (98.4) 97.5 (98.4)
 No.  data  >2σI (%) 83.2 (58.5) 82.5 (60.8) 76.6 (42.2)
 I/σI  19.3 (3.8) 15.8 (3.9) 10.7 (2.3)
 R merge/sym
<REF>a
</REF> (%) 7.3 (41.2) 8.9 (42.0) 9.8 (54.0)
Refi  nement statistics
 Nonhydrogen  atoms
 Protein 3,528 3,542 7,084
 Water 55 123 32
Resolution (Å) 65.65-2.4 65.51-2.2 60.86-2.6
Rcryst
<REF>b
</REF> (%) 23.0 21.0 20.7
Rfree
<REF>c
</REF> (%) 27.1 27.8 25.6
RMS deviations from ideality
  Bond lengths (Å) 0.007 0.011 0.009
  Bond angles (°) 1.05 1.28 1.20
 Dihedrals  (°) 28.57 28.82 28.69
 Impropers  (°) 1.25 1.33 1.27
Ramachandran plot
 Most  favored 90.7 89.9 87.9
  And allowed region (%) 9.1 9.3 10.8
  And disallowed region (%) 0.2 0.8 1.3
B-factors (Å2)
  Average main chain 33.8 28.4 41.3
  Average side chain 34.3 30.5 42.8
  Average water molecule 28.2 30.8 43.5
  RMS deviation bonded Bs 1.6 2.5 2.3
Values in parentheses are for the highest resolution shell.
<REF>a
</REF>Rmerge/sym = ∑|Ihkl – ∑〈Ihkl〉/∑Ihkl.
<REF>b
</REF>Rcryst = ∑hkl||Fo| − |Fc||/∑hkl|Fo| for all data except as indicated in footnote “c.”
<REF>c
</REF>7.3, 5.2, and 5% were used for the Rfree calculation for NKT12 (orthorhombic), NKT15 (orthorhombic), and NKT15 (trigonal), respectively.
RMS, root mean square.664  STRUCTURE OF THE INVARIANT NKT CELL RECEPTOR | Kjer-Nielsen et al.
The overall structure of the NKT12 TCR comprises four 
immunoglobulin-like domains with a constant (C) and vari-
able (V) domain per chain (Fig. 2 A). [ID]FIG2[/ID] The V domain is com-
posed of three CDRs; together, these six hypervariable loops 
form a potential ligand-binding site for the NKT12 TCR. 
Accordingly, the structure of the NKT12 TCR generally re-
sembles that of other αβ TCRs. The interface between the 
α- and β-chains of the NKT12 TCR is extensive (buried 
surface area [BSA] of ≈4,100 Å2), with the V and C domains 
packing against each other. The BSA at the Vα-Vβ and Cα-
Cβ interfaces, ≈1,400 Å2 and ≈2,700 Å2, respectively, falls 
within the range observed previously in other TCR struc-
tures (35, 36). Comparative structural analyses will be mainly 
restricted to two intact heterodimeric TCR crystal structures, 
namely a human nonliganded immunodominant TCR, 
LC13 (36, 37), and the nonliganded murine TCR, 2C (38, 
39). The root mean square (RMS) for the pairwise superpo-
sitions between the NKT12 TCR and the LC13 and 2C 
TCRs were 1.20 Å (383 residues) and 1.43 Å (345 residues), 
respectively. As expected, the constant domains of the 
NKT12 TCR superpose very closely with that of another 
nonliganded human TCR, LC13 (RMS deviations 0.50 Å 
and 0.47 Å over the Cα and Cβ domains, respectively). 
However signifi  cant diff  erences in juxtaposition between 
the Vα and Vβ domains were observed, which refl  ects the 
unique interchain pairing of the semi-invariant NKT TCR. 
For example the Vβ domain of NKT12 is rotated 16.4° and 
13.1° relative to the 2C TCR (38, 39) and the LC13 TCR, 
respectively (36, 37). Moreover, comparative analyses re-
vealed structural divergence within the respective Vα and Vβ 
domains. For example, pairwise superpositions between 
NKT12 Vα and the LC13 and 2C Vα domains were 1.40 Å 
(94 residues) and 1.34 Å (92 residues), respectively; whereas 
the pairwise superpositions between the Vβ domains (LC13, 
1.08 Å [98 residues]; 2C, 1.02 Å [103 residues]) revealed that, 
in comparison, the Vα domain was more divergent than the 
Vβ domain. The major structural diff  erences within the V 
domains reside in the hypervariable loops and the loop (69α-
74α), which impacts not only upon the Ag binding site, but 
also the Vα-Vβ pairing.
The NKT12 Vα–Vβ interface is composed of the f-g and 
the c-c' strands, and their interconnecting loops from each 
domain crossing over each other, and accordingly utilizes 
both the Vα24 and Jα18 gene segment of the invariant chain 
(Supplemental Materials and methods, available at http://
www.jem.org/cgi/content/full/jem.20051777/DC1). The 
CDR3α and CDR3β loops sit centrally at this interface, 
abutting each other (Fig. 2 and Supplemental Materials and 
methods). At the Vα–Vβ interface, there are six polar inter-
actions, fi  ve water-mediated polar interactions, two salt bridges, 
and a multitude of van der Waals interactions that include a 
cluster of aromatic residues (Tyr35α, Phe106α, Tyr33β, 
Tyr35β, Tyr107β) (Table S1, available at http://www.jem.
org/cgi/content/full/jem.20051777/DC1). This cluster is 
largely conserved, although less extensive in the LC13 and 
2C TCR structures.
The sequences encoded by the invariant Jα and hyper-
variable Dβ-N-Jβ region create the CDR3 loops (Fig. 2, A 
and B). Accordingly, the interface diff  ers slightly between the 
NKT12 and NKT15 TCRs as a result of the conformation of 
the diff  erent CDR3β loops (Fig. 2 C). Notably, the CDR1α 
and CDR2α loops adopt a conformation that is diff  erent 
from previously determined canonical CDR conformations 
(40), whereas CDR1β and CDR2β adopt canonical confor-
mations β1-1 and β2-1, respectively (Table S2, available at 
http://www.jem.org/cgi/content/full/jem.20051777/DC1). 
The conformation of the CDR3α loop is well ordered and 
stabilized by interloop interactions as shown for other highly 
selected TCRs (34).
Figure 2.  Overview of NKT cell TCR structure showing the confor-
mation of the CDR loops at the Ag-binding interface. (A) Overview of 
the structure of NKT12 with the α-chain and β-chain shown in gray and 
pink, respectively. (B) The CDR3 loops of NKT12 are color coded according 
to their genetic origin. (C) Superimposition of the CDR loops of the NKT12 
and NKT15 TCRs depicting the difference in the conformation of CDR3β 
(NKT12, CDR loops colors are indicated; NKT15, orange).JEM VOL. 203, March 20, 2006  665
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The ligand binding surface contains a preformed cavity 
suited to Ag binding
The ligand-binding surface of NKT12 contains a central wa-
ter-fi  lled cavity that is markedly electropositive and  120 Å3 
in volume (Fig. 3, A and B). [ID]FIG3[/ID] The cavity is lined by residues 
from CDR1α and CDR3α of the invariant NKT α-chain, as 
well as CDR1β and CDR3β of the semi-invariant β-chain 
that collectively make several direct and water-mediated in-
teractions with each other (Fig. 3 B). The residues from the 
invariant Vα24-N-Jα18 include the following: Ser30α and 
Asn31α from CDR1α; Arg33α from the Vα-framework 
close to CDR1α; Ser93α from the CDR3α V-J junctional 
region; and Gly96α, Ser97α, and Leu104α, all from the 
CDR3α Jα segment. Remarkably, Arg33α that forms the 
electropositive base of the cavity is unique to Vα24 among all 
the human Vα genes and is also conserved in mouse Vα14 
and in only one other Vα family (TRAV7). Similarly, the Jα 
residues Gly96α, Ser97α, and Leu104α are only found in 
Jα18. The Vβ framework residue Tyr33β, adjacent to the 
CDR1β, also lines the cavity and is conserved in mouse and 
human NKT Vβ regions. The NKT15 TCR is virtually 
identical in structure to NKT12, apart from the amino acid 
sequence and conformation of its CDR3β regions. These 
diff  erences include two extra residues encoded by the Dβ-N 
region, thereby introducing a charged, surface-exposed 
“RDR” motif that forms the tip of CDR3β in the NKT15 
TCR. Thus, the hypervariable CDR3β residues that line the 
cavity of NKT12 include Thr95β, Ser96β, Ser100β, and 
Tyr101β; whereas, in NKT15, the corresponding residues 
lining the cavity are Ser95β, Gly96β, Leu97β, and Gly101β 
(Fig. 3, C and D; Table I). Although the positively charged 
cavity at the Ag-binding interface is conserved between 
NKT12 and NKT15, in the trigonal crystal form, the en-
trance to the cavity is occluded by the bulky Tyr103β (Jβ) 
from the CDR3β loop of NKT15 (Fig. 3 C). Notably, how-
ever, this region of the CDRβ loop is relatively mobile, such 
that Tyr103β was unresolved in the orthorhombic crystal 
form. This suggests that Tyr103β could be easily displaced, 
allowing access of potential ligands to this conserved region 
(Fig. 3 D). The cavity at the ligand interface could potentially 
accommodate small polar moieties such as the galactose ring 
of α-GalCer that projects out of the antigen-binding cleft of 
CD1d (14, 15) (Fig. S1, available at http://www.jem.org/
cgi/content/full/jem.20051777/DC1). This would be con-
sistent with a direct interaction between NKT TCRs and the 
glycosyl head group of α-GalCer bound to CD1d, as pre-
dicted from many studies and analogous to what has been 
proposed for CD1b/glycolipid recognition (41). The volume 
of the cavity would be predicted to vary according to the 
structure and fl  exibility of the CDR3β sequences; this might 
facilitate interaction with other glycolipid head groups.
The CDR3𝗃 hypervariable loop modulates antigen specifi  city
Previous studies have shown that mouse Vβ8.2+ NKT TCRs 
can be substituted with Vβ8+ chains from non–NKT cells 
without loss of binding affi   nity to mCD1d/α-GalCer (28), 
suggesting that the CDR3β region plays little or no role in 
NKT cell specifi  city, at least to this antigen complex. How-
ever, the structure of the NKT12 and NKT15 TCRs showed 
that some CDR3β residues line parts of the cavity at the li-
gand interface, where they could modulate Ag specifi  city. 
We examined the role of CDR3β by assessing how variation 
in this region aff  ects cross-species reactivity with CD1d/α-
GalCer. We fi  rst measured the affi   nity of NKT12, NKT15, 
and NKT18 TCRs for α-GalCer complexed to mCD1d and 
hCD1d using surface plasmon resonance (SPR) (Table S3 
and Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20051777/DC1, and NKT18 not depicted). This 
allows a direct examination of the impact of the variable 
CDR3β region on the TCR interaction. The affi   nity of the 
NKT12 and NKT15 TCRs was approximately twofold 
higher for hCD1d/α-GalCer (Kd(eq)   10  μM) versus 
mCD1d/α-GalCer (Kd(eq)  20 μM), whereas the affi   nity of 
the NKT18 TCR was similar for human and mouse CD1d/
α-GalCer (Kd(eq)  20 μm). Although these affi   nity diff  er-
ences with mCD1d/α-GalCer were small, they were repro-
ducible, indicating a subtle but measurable infl  uence  of 
CDR3β on NKT TCR specifi  city.
Figure 3.  The Ag-binding interface of NTK12 and NKT15 TCRs 
contains a preformed cavity created by invariant residues of the 
𝗂-chain, a species-conserved residue from the 𝗃-chain and 
CDR3𝗃. (A) NKT12 TCR α-chain residues that are conserved between 
human and mouse are red; α-chain residues that differ between these 
species are gray. The TCR β-chain residue Tyr33β is conserved across 
species, whereas the CDR3β residues are divergent between species. 
β-chain side chains are green. (B) Close-up of residues forming the 
  putative ligand-binding cavity of the NKT12 binding surface. Residues 
are labeled according to the single amino acid code. (C) The putative 
ligand-binding cavity of NKT15 is obstructed by the bulky side chain of 
residue Tyr 103β from CDR3β in the trigonal form of the crystal structure. 
(D) Tyr103β could not be visualized in the NKT15 TCR crystal comprising 
the orthorhombic space group. The high mobility of Tyr103β could easily 
allow displacement of this side chain, exposing the putative Ag-binding 
cavity. Accordingly, the Tyr103β side chain has been omitted, revealing 
the cavity.666  STRUCTURE OF THE INVARIANT NKT CELL RECEPTOR | Kjer-Nielsen et al.
We next studied the binding of several hybrid TCRs 
with switched or mutated CDR3β regions (Fig. 4 and Table 
S4, available at http://www.jem.org/cgi/content/full/
jem.20051777/DC1). [ID]FIG4[/ID] The native integrity of these chimeric 
receptors was intact based on their binding with a conforma-
tion-dependent mAb 12H8 (34) and their behavior by gel 
fi  ltration and SDS-PAGE (unpublished data). First, we ex-
amined the relative roles of the CDR1β and CDR2β, versus 
the hypervariable CDR3β residues (encoded by Dβ-N-Jβ 
gene segments) of NKT15, by swapping the entire NKT15 
TCR β-chain for that of the classical MHC I–restricted TCR 
LC13 (36, 37) (Fig. 4 B). This TCR contains a diff  erent Vβ 
chain (Vβ6.2 or TRBV7-8*03) to NKT15, but uses the 
same Jβ segment to create the CDR3β loop (TRBD1/D2; 
TRBJ2-7*01). The hybrid NKT15α/LC13β TCR lost vir-
tually all CD1d/α-GalCer binding as measured by both SPR 
and by failure to inhibit NKT cell staining by CD1d/α-Gal-
Cer tetramer (Fig. 4 B). Although this fi  nding suggests that 
either CDR1β and/or CDR2β may be crucial for CD1d/α-
GalCer binding, it could also be explained by an incompati-
bility in the LC13 CDR3β region. Therefore, a chimeric 
TCR was generated where just the CDR3β loop of NKT15 
was replaced with the corresponding loop of LC13 (also 
  encoded by Jβ TRBJ2-7) (Fig. 4 B). This swap shortens 
the CDR3β loop of NKT15 by three residues and alters the 
  sequence of buried amino acids involved in stabilizing the 
TCR α-chain as well as changing the solvent-exposed resi-
dues at the tip of the loop (Table S4). The hybrid TCR had 
Figure 4.  NKT cell receptor CDR3𝗃 regions impact on the recog-
nition of CD1d/𝗂-GalCer. (A) Conformation of the CDR3 loops of the 
NKT15 TCR revealing the highly exposed “RDR” motif at the tip of the 
CDR3β loop. (B) Inhibition of NKT cell staining by recombinant wild-type 
and chimeric NKT TCRs. TCRs comprised LC13αβ; NKT15αβ; NKT15α-
chain/LC13 β-chain; NKT15α-chain/NKT15 β-chain engrafted with the 
LC13 CDR3β-loop; and NKT15α-chain/NKT15β-chain with “RDR” to 
“AAA” substitution within the CDR3β loop. Graded concentrations of 
soluble recombinant TCRs were preincubated with phycoerythrin-labeled 
tetramers of mCD1dα-GalCer. These were used to costain mouse thymo-
cyte cells with anti-CD3 mAb and analyzed by fl  ow cytometry. Shown are 
fl  ow cytometry plots with tetramer-staining after preincubation with 
500 μg/ml TCRs. *, the inhibition observed with maximal concentrations 
of the NKTα+LC13(CDR3β) (500 μg/ml) was only partial, and equivalent 
to the inhibition observed with 8 μg/ml (not depicted) of NKT15. The 
indicated KD values are calculated from SPR studies of TCR binding to 
immobilized human and mouse CD1dα-GalCer (Table S3 and Fig. S2 for 
NKT12 and NKT15). LC13 is a control TCR from an HLA-B8–restricted, 
virus-specifi  c CTL; ND, KD not measurable. (C) Superposition of the 
CDR3β loop of LC13 in the context of the NKT CDR3α based on the 
known structure of LC13 ( <CIT>references 36, 37 </CIT>). The LC13 CDR3β loop is 
predicted to impact on the conformation of CDR3α and to disrupt access 
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an  5–10-fold lower affi   nity by SPR measurements than 
NKT15 bound to both human and mouse CD1d/α-GalCer. 
In addition, the hybrid TCR required  60-fold higher con-
centrations than NKT15 to achieve comparable inhibition of 
staining of mouse NKT cells with mCD1d/α-GalCer tetra-
mers (Fig. 4 B). However, the structures of the LC13 (36, 37) 
and NKT15 TCRs suggested that the orientation of the 
LC13 CDR3β was likely to sterically impact on the confor-
mation of the NKT15 CDR3α loop, thereby indirectly af-
fecting the putative binding cavity and disrupting ligand 
recognition by the hybrid TCR (Fig. 4 C). Notwithstanding 
these fi  ndings, the CDR3β loops of other NKT TCRs show 
substantial variation (26, 27, 42), suggesting that sequence 
variation at the solvent-exposed tips of the CDR3β loops 
might be well tolerated. To this end, we made a triple alanine 
mutant in the 98RDR100 sequence (encoded by Dβ-N), 
which is highly solvent accessible and, as such, their mutation 
is not predicted to aff  ect the conformation of the CDR3α 
loop (Fig. 4 A). SPR-binding studies of this “AAA” mutant 
NKT15 TCR revealed its affi   nity for both human and mouse 
CD1d/α-GalCer was comparable to the wild-type NKT15 
(Fig. 4 B), indicating these three exposed residues are not 
critical to the affi   nity of the interaction. In addition, this hy-
brid TCR inhibited staining of mouse NKT cells by mCD1d/
α-GalCer tetramers at the same concentration as NKT12 and 
NKT15 TCRs (Fig. 4 B).
Collectively, our data suggest that the function of the 
CDR3β region is to modulate NKT cell recognition of dif-
ferent glycolipids. Although this modulation of specifi  city 
sometimes results in sterically abolishing recognition alto-
gether, as in the substitution of the LC13 CDR3β region in 
NKT15, the concept is consistent with a high degree of 
structural variation being tolerated in this region without loss 
of affi   nity.
Cross-species reactivity of NKT cells with CD1d/𝗂-GalCer
Unlike the highly restricted recognition of MHC I mol-
ecules by conventional αβ TCRs, NKT cell TCRs (includ-
ing NKT12, 15, and 18) show a remarkable cross-species 
reactivity, implying evolutionary conservation of an impor-
tant immune specifi  city and function (33). The invariant 
TCR α-chain from human NKT cells has 54% sequence 
identity with its mouse counterpart, whereas the human 
Vβ11 and mouse Vβ8.2 share 65% sequence identity. This 
cross-species identity is particularly marked in the CDR3α 
and CDR1α loops in which 10/13 and 2/6 residues, re-
spectively, are identical between human and mouse se-
quences (Fig. 5). [ID]FIG5[/ID] Moreover, the two identical residues in 
the CDR1α are surface exposed. The CDR3α and CDR1α 
residues that are conserved across species form part of an 
extensive, contiguous surface at the ligand-binding inter-
face of the NKT TCRs (Fig. 5 A). Based on the mode of 
recognition of MHC–peptide complexes (35), this region 
of the TCR would be expected to make interactions with 
the CD1d–glycolipid complex. In addition, the CDR3α 
and CDR1α loops make numerous interloop interactions 
involving residues that are largely conserved between the 
human and mouse semi-invariant NKT TCRs. These intera-
ctions are important in stabilizing the conformation of the 
CDR loops.
Notably, 0/6 of the amino acids in the human and mouse 
CDR2α loop are identical, although the Phe51 (human) 
Figure 5.  Conserved residues from human and mouse NKT TCR 
CDR1𝗂, CDR3𝗂, and CDR2𝗃 loops form a contiguous conserved 
surface that is adjacent to the putative Ag-binding cavity. The dif-
ferent conserved CDR regions are colored to correspond to the sequence 
alignment of mouse and human CDR loops. All other conserved and semi-
conserved residues are brown and orange, respectively, in the alignment 
and are not shown in the structure. The TcR α-chain is white and the TCR 
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  versus His51 (mouse) residues are relatively conserved (Fig. 
5 B). This observation is consistent with the natural allelic 
polymorphism in the mouse Vα14 gene (TRAV11*01 vs. 
TRAV11*02) in which 3/7 CDR2α residues contain non-
conservative substitutions that have minimal impact on TCR 
affi   nity for CD1d/α-GalCer (43). These fi  ndings suggest a 
minor role for CDR2α residues in mediating cross-species 
CD1d reactivity.
In the TCR β-chain, only the CDR2β shows signifi  cant 
sequence identity between mouse and human TCRs that 
share 4/6 residues at the tip of this loop, and 4 amino-termi-
nal residues (45LIHY48) and 5 carboxy-terminal residues 
(55TEKGD59) either side of the tip of the loop. Notably, the 
surface exposed CDR2β loop, and the highly conserved “hot 
spot” formed by the CDR3α and CDR1α loops merge to 
create an even more extensive species-conserved region at 
the ligand interface (Fig. 5). Accordingly, this region of the 
TCR is likely to play a crucial role in CD1d–glycolipid in-
teractions by mediating restricted recognition and cross-spe-
cies reactivity. In contrast with the CDR2β loop, the CDR1β 
loop is only moderately conserved across human and mouse 
sequences. However, as outlined earlier, there are fi  ve further 
cross-species conserved residues that line the cavity at the li-
gand interface of the NKT TCR: Tyr33β, Arg33α, Gly96α, 
Ser97α, and Leu104α.
Collectively, the structures of NKT12 and NKT15 sug-
gest that the species conservation of CDR3α, CDR1α, and 
CDR2β loops creates a contiguous conserved hot spot. It is 
highly likely that this hot spot and the collection of conserved 
residues forming the cavity at the ligand-interface are crucial 
in mediating the reciprocal cross-species reactivity between 
human and mouse NKT TCRs.
Proposed docking of NKT TCR onto CD1d/𝗂-GalCer
The NKT TCR structure, together with the recently pub-
lished CD1d/α-GalCer structures and previous mutagenesis 
experiments, has allowed us to propose a model for the inter-
actions between the NKT TCR and CD1d/α-GalCer. For 
several reasons, the model was based on the LC13–HLA–B8–
FLR complex. First, we examined all the TCR–MHC-I-p 
complexes solved to date and the LC13 complex provided the 
best approximation for docking of the central TCR pocket 
over the α-GalCer head group. Second, like α-GalCer, the 
peptide determinant recognized by LC13 is a minimally pro-
truding Ag and is similarly located to the glycosyl head group 
of α-GalCer. Moreover, LC13 also has a central pocket that 
accommodates the main side chain of the ligand as proposed 
for NKT TCRs. Despite the known caveats of any structural 
estimation, the model provides plausible insight into NKT 
TCR recognition of hCD1d/α-GalCer and is consistent 
with several published observations. Thus, in both the mouse 
and human CD1d molecules, the conserved residues Arg79, 
Asp80, Glu83, and Asp153 (Asp 151 in hCD1d) are critical 
for presentation of α-GalCer by CD1d (44). Of these amino 
acids, Arg79 and Asp153, but not Glu83, make interactions 
with α-GalCer (14, 15). However, mutagenesis studies sug-
gest that all three can infl  uence recognition by the NKT 
TCRs (17, 44, 45), perhaps directly or by aff  ecting the orien-
tation of the α-GalCer glycosyl head group. Taking these is-
sues into consideration, the model is consistent with diagonal 
docking of the NKT TCR over the ligand-binding domain of 
CD1d (Fig. 6).[ID]FIG6[/ID] Because α-GalCer protrudes only minimally 
from the CD1d cleft, the NKT TCR forms considerable 
contacts with CD1d. Thus, the CDR1α and CDR2α loops 
are primarily positioned over the α2 helix, interacting with 
hCD1d residues spanning Trp153–Trp160. The aromatic 
Figure 6.  Proposed docking of NKT TCR onto CD1d/𝗂-GalCer. (A) In 
the model, the NKT12 α and β chain are shown in gray and pink, respec-
tively, and the CDR loops are red (CDR1α), green (CDR2α), blue (CDR3α), 
magenta (CDR1β), yellow (CDR2β), and cyan (CDR3β). α-galactosylce-
ramide is shown in orange within the antigen-binding domain of hCD1d 
(purple). (B) View of the antigen-binding cleft of human CD1d–presenting 
α-GalCer (orange). The CDR footprint of the proposed docking model of 
NKT12 is shown for reference and the CDR loops are colored as in A. 
  Surface-exposed residues on the α1 and α2 helices of hCD1d are shown. 
Residues in red had an impact on NKT activation by mCD1d in the pub-
lished literature. Residues in white either had no impact or were not in-
vestigated. Residues in yellow are those residues likely to be important in 
the docking of NKT12 onto CD1d/α-galactosylceramide according to our 
proposed model.JEM VOL. 203, March 20, 2006  669
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residue Phe51α (His51 in mouse), located within the 
CDR2α loop, could potentially stack neatly between the 
two bulky aromatic rings of Trp153 and Trp160 of hCD1d. 
The CDR1β and CDR2β loops docks over the α1 helix 
of CD1d, interacting with a localized stretch of CD1d resi-
dues (75–83). Although CDR2β is located on the periphery, 
our model suggests that the prominent Tyr48β packs against 
Ser75 and the aliphatic moiety of Arg79 in CD1d. Moreover, 
our model suggests a potential salt bridge between Arg79 and 
Asp30β of the CDR1β loop. This is consistent with a role 
for Arg79 independent of its interactions with α-GalCer, as 
an important residue for recognition of CD1d/α-GalCer by 
many NKT TCRs. Notably, however, substitution of this 
residue can be tolerated by certain NKT cells indicating a 
variable contribution of Arg79 contingent upon the nature of 
the glycolipid Ag (44). The conserved TCR residues Asp94α, 
Arg95α, and Arg103α are solvent exposed and proximal to 
the binding interface cavity, where their charged nature pro-
vides the potential for complementary electrostatic interac-
tions with one or more of these CD1d residues.
Both the CDR3α and CDR3β loops make contact with 
the galactose moiety of α-GalCer in the model; however, the 
CDR3α loop is also predicted to interact extensively with the 
α1 helix (spanning residues 65–72) of CD1d. Thus, the con-
served residues within the CDR3α loop are proposed to me-
diate interactions with conserved residues on CD1d accounting 
for the inherent bias of this TCR in ligating CD1d. The 
prominent role of CDR3α in interacting with CD1d may ex-
plain NKT cross-reactivity between mouse and human CD1d, 
analogous to the way that the CDR3α loop of the LC13 
TCR is suggested to dictate its known   alloreactivity (34).
Upon ligation, the surface-exposed galactose of α-GalCer   
is “walled” by the CDR3α and CDR3β loops such that
the galactose is positioned within the electropositive pre-
formed cavity. The galactose head group of α-GalCer is 
likely to interact with residues lining the pocket, including 
Asn31α, Arg33α, Gly96α, Ser97α, and Lys31β. The role of 
Arg33α may involve specifi   city interactions analogous to 
those observed in the LC13 TCR binding pocket, where 
His33α at the base of the pocket makes a water-mediated 
bond to a critical peptide side-chain from the ligand (37).
Larger Ag headgroups, such as the tri-hexosyl moiety of 
the glycosphingolipid iGb3 (7, 8), are likely to be partially 
accommodated via movement in the CDR3 loops. This is 
consistent with the observed plasticity of αβTCRs in engag-
ing with pMHC molecules. We predict that the fl  exible 
CDR3β loop will allow modulation of NKT cell recogni-
tion of diff  erent glycolipids. Therefore, the extent of the pre-
formed cavity volume is likely to change, depending on the 
position of the CDR3β loop. This is consistent with a high 
degree of structural variation being tolerated in this region 
without loss of affi   nity to ligands such as α-GalCer.
D  I  S  C  U  S  S  I  O  N 
NKT cells straddle the roles of both innate and adaptive cel-
lular immune responses (46). They respond rapidly upon 
  antigen recognition by their semi-invariant TCR, producing 
a variety of cytokines that can regulate tumor immunity, au-
toimmunity, and allergy and can orchestrate protective re-
sponses to infectious agents (2, 47–49). Despite expressing a 
semi-invariant TCR, NKT cells are reported to be selected 
or activated by diff  erent glycolipid molecules such as the ma-
rine sponge-derived α-GalCer (6), a phosphoethanolamine 
(50), PIM4 (11), α-glycuronosyl-ceramides (8–10, 51, 52), 
sulfated variants thereof (10), a tumor-derived ganglioside 
GD3 (31), self-antigens including some forms of β-galacto-
sylceramide (53, 54), and isoglobotrihexosylceramide (iGb3) 
(7). This capacity to recognize a variety of foreign and self-
derived glycolipid Ags refl  ects the increasingly diverse func-
tional roles ascribed to NKT cells (47–49) and highlights the 
need for a structural explanation as to how the semi-invariant 
NKT TCR can achieve such a diversity of recognition. 
Abundant evidence suggests that the glycosyl head group of 
the glycolipid sugar moiety is a critical determinant recog-
nized by the NKT TCR (14–16, 29, 44, 45, 55, 56). Thus, 
the NKT TCR binds effi   ciently to CD1d complexed with 
α-GalCer but not with β-GalCer containing similar sphin-
gosine and acyl chains (56), consistent with the lipid chains 
being buried in the Ag-binding cavity, whereas the glycosyl 
head group protrudes out of the cleft (14, 15). It is notable 
that the small target created by the polar head of α-GalCer 
induces a highly selected “immunodominant” αβ TCR rep-
ertoire. This bias is reminiscent of the highly restricted CTL 
repertoires toward minimally exposed (36, 57, 58) or highly 
unusual viral determinants (59–61).
These observations would be consistent with the cavity at 
the ligand interface of the NKT12 and NKT15 TCRs acting 
as a preformed Ag pocket. The structures of CD1d/αGalCer 
have led to speculation that the CDR3α of the NKT TCR 
would be placed over the galactose ring (14). This mode of 
interaction fi  ts the idea that the cavity might envelope the 
polar glycosyl head group of α-GalCer and some related 
  antigens. Supporting this interpretation, the walls of the cavity 
are formed from unique amino acids present in the Vα-
  domain (CDR1α and Arg33α) and CDR3α regions of the 
invariant TCR α-chain. Moreover, these regions are highly 
conserved between mouse and human NKT TCRs that are 
functionally cross-reactive (62). In addition, CDR1β and 
CDR3β residues also contribute to the cavity wall, providing 
a mechanism by which the CDR3β could modulate Ag 
specifi   city. Many studies have reported heterogeneous 
CDR3β usage by NKT cells, suggesting that these loops do 
not play a key role in NKT cell recognition (25–28). How-
ever, our data indicate that not all CDR3β sequences support 
recognition of CD1d–glycolipid complexes and this is prob-
ably the result of steric hindrance by some CDR3β loops that 
obstruct the cavity interface and/or interfere with the con-
formation of the highly conserved CDR3α loops.
The binding kinetics and affi   nities of the human NKT12, 
NKT15, and NKT18 TCRs for hCD1d/α-GalCer are typi-
cal of conventional αβTCR–MHCp interactions with KD 
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binding of recombinant mouse NKT TCRs, where the KD 
values are reported to be  0.1–0.3 μM (28, 45). These dif-
ferences presumably refl  ect species variability despite the re-
markable reciprocal cross-reactivity of human and mouse 
NKT cells. This cross-reactivity correlates with a conserved 
hot spot at the NKT TCR interface that comprises a contig-
uous surface suitable for interacting with CD1d–glycolipid 
complexes. Additional conserved residues forming the cavity 
at the ligand interface are also likely to contribute to the re-
ciprocal cross-species reactivity. Despite the cross-species in-
teractions, the glycosyl head group of α-GalCer is shifted by 
up to 3 Å between the mouse and human structures, which 
is likely to impact on the recognition of the galactose moiety 
itself (63). Human CD1d has a tryptophan residue at position 
153 that pushes the galactose head group away, whereas, in 
mouse, the equivalent amino acid (position 155) is a much 
smaller glycine residue (14, 15). The previously reported lack 
of temperature dependence in the binding affi   nity of mouse 
NKT TCRs with CD1d-αGalCer suggests a rigid “lock and 
key” mode of binding (28, 56). However, the cross-reactiv-
ity of human and mouse NKT TCR for CD1d–α-GalCer 
implies that NKT TCR recognition has considerable struc-
tural plasticity more typical of αβTCR–MHC-I interactions 
and potentially important in the recognition of diff  erent gly-
colipid antigens.
How can NKT cells, with a semi-invariant TCR, recog-
nize a diversity of glycolipid antigens with structurally dis-
tinct carbohydrate head groups? Although this can only be 
defi  nitively answered with direct structural studies, the re-
cently defi  ned α-glucuronosylceramides (8–10, 51, 52) are 
structurally very similar to α-GalCer and α-glucosylceramide 
and thus conceivably would fi  t into the same TCR cavity. It 
is also possible, or even likely, that only a minor subset of 
fresh human NKT cells recognize some of these more re-
cently defi  ned antigens. For example, <10% of NKT cells 
were labeled by PIM4-loaded CD1d tetramers (11) and the 
labeling was 10–100-fold weaker than for α-GalCer-loaded 
CD1d tetramers. Similarly, although in mice most NKT cells 
depend on iGb3 for thymic selection (7), it is not proven that 
iGb3 is a key selecting ligand for human NKT cells (64). 
Moreover, given that mouse NKT cells do not stain with 
CD1d/iGb3 tetramers (7), their affi   nity for NKT TCRs is 
likely to be very low, suggesting that the tri-hexosyl head 
group of this Ag might be poorly recognized in comparison 
to the galactosyl head group of α-GalCer. Furthermore, the 
extent to which fresh human NKT cells recognize other gly-
colipid ligands such as GD3 (31) and phosphoethanolamine 
(50) is unknown. Notwithstanding these concerns, it is not 
inconceivable that diff  erent sugar groups could be accom-
modated within the pocket by a degree of plasticity in the 
CDR3 loops and in particular the CDR3β loop, which was 
shown to exhibit a degree of fl  exibility in our study.
Collectively, our fi  ndings suggest a basis for the semi-
  invariant nature of NKT TCRs in which highly conserved 
residues in the α- and β-chains of the TCR contribute to 
binding of glycolipid head groups through a discrete cavity at 
the ligand interface. Other conserved features of the NKT 
TCR appear to play a role in CD1d binding, whereas plastic-
ity of antigen recognition is preserved through variation in 
CDR3β loops and the intrinsic adaptability of other CDR 
loops at the ligand interface. Furthermore, our proposed 
model of the complex suggests that the CDR3α loop plays a 
prominent role in determining Ag specifi  city as well as dic-
tating the observed cross-species reactivity via interactions 
with CD1d. It will be intriguing to visualize this plasticity in 
complexes of NKT TCRs with a variety of CD1d/glycolipid 
antigens and to correlate the modes of interaction with func-
tional diversity in NKT cells.
MATERIALS AND METHODS
Protein expression, refolding, and purifi  cation. cDNAs encoding 
NKT cell receptors and CD1d were derived as described in the Supplemen-
tal Materials and methods. Inclusion body protein of the NKT TCRα and 
NKT TCRβ chains were prepared essentially as described previously (36, 
37, 65). 64 mg TCRα and 32 mg TCRβ inclusion body proteins were 
thawed, pulsed with 1 mM DTT, combined, and injected into 800 ml of 
stirring refolding buff  er containing 100 mM Tris, pH 8.5, 5 M urea, 0.4 M 
arginine, 0.5 mM oxidized glutathione, 5 mM reduced glutathione, 2 mM 
EDTA, 0.2 mM PMSF, and 1 μg/ml Pepstatin A at 4°C. Equal amounts of 
the NKT TCRα and NKT TCRβ chain inclusion body proteins were 
added 16 h later. After 24 h, refolded protein was dialyzed against 10 mM 
Tris-HCl, 0.1 M urea, pH 8, and subsequently against 10 mM Tris-HCl. 
Dialyzed protein was captured on a column containing DEAE Sepharose 
Fast Flow (GE Healthcare), and eluted with 10 mM Tris-HCl, 200 mM 
NaCl. Eluted NKT TCR was concentrated and loaded unto a HiLoad 
  Superdex 75 pg gel fi  ltration column (GE Healthcare) in the presence of 
10 mM Tris-HCl, 150 mM NaCl. Fractions containing the TCR were 
pooled and purifi  ed further on a Mono-Q column (GE Healthcare). Peak fractions 
were pooled and concentrated before one more purifi  cation by gel fi  ltration 
as described earlier in this paragraph. Peak fractions were concentrated to 
10–20 mg/ml and were used subsequently in crystal trials.
Crystallization. Rod-shaped crystals of the NKT TCRs were grown at 
12 mg/ml by the hanging drop vapor diff  usion technique and at room tem-
perature. NKT12 crystals grew in 18% PEG 3350, 0.1 M cacodylate, pH 
6.3, 0.2 M lithium chloride, and NKT15 crystals grew in 9% PEG 3350, 
0.1 M cacodylate, pH 6.4, 0.2 M ammonium acetate. The crystals belong to 
space group C2221 and the unit cell dimensions were consistent with one 
molecule per asymmetric unit (Table II). NKT15 crystals were also grown in 
0.2 M sodium sulfate. 20% PEG 3350, pH 6.6. These crystals belong to space 
group P32, with unit cell dimensions consistent with two molecules per 
asymmetric unit (Table II).
Structure determination and refi  nement. The crystals were fl  ash frozen 
before data collection using up to 15% glycerol as the cryoprotectant. The 
data were processed and scaled using the HKL package. Datasets of 2.2, 2.4, 
and 2.6 Å resolution were collected at the BioCars beamline using a Quan-
tum 4 CCD detector (Table II). The crystal structures were solved using the 
molecular replacement method, as implemented in MOLREP (66), using 
the unliganded LC13 (37) structure as the search model, where the LC13 
CDR loops were initially removed and all other nonidentical residues were 
mutated to alanine. Unbiased features in the initial electron density map 
confi  rmed the correctness of the molecular replacement solution. The prog-
ress of refi  nement was monitored by the Rfree value with neither a sigma, nor 
a low resolution cut off   being applied to the data. Initially, the structures 
were refi  ned using rigid-body fi  tting of the individual domains followed by 
the simulated-annealing protocol implemented in CNS (version 1.0) (67). 
Later, translation, libration, and screw-rotation displacement (TLS) refi  ne-
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with rounds of model building using the program “O” (69). Tightly re-
strained individual B-factor refi  nement was used, and bulk solvent correc-
tions were applied to the data set. Water molecules were included in the 
model if they were within hydrogen-bonding distance to chemically reason-
able groups, appeared in Fo − Fc maps contoured at 3.5σ, and had a B-factor 
of <60 Å2. The structures have been deposited in the PDB (accession nos. 
<PDB>2EYR, 2EYS, 2EYT </PDB>).
Biotinylation of CD1d and loading with 𝗂-GalCer. Biotinylated 
CD1d was mixed with α-GalCer at a molar ratio of 1:3 (protein:lipid) at 
room temperature overnight. Loaded CD1d protein was then purifi  ed from 
free α-GalCer and buff  er exchanged into 10 mM Hepes-HCl, pH 7.4, 150 
mM NaCl, and 0.005% surfactant P20 using a HiLoad Superdex 200 pg gel 
fi  ltration column (GE Healthcare). Protein quality was monitored by its gel 
fi  ltration profi  le and mobility on SDS-PAGE.
SPR binding studies. All SPR experiments were conducted at 25°C on a 
Biacore 3000 instrument using HBS buff  er (10 mM Hepes-HCl, pH 7.4, 
150 mM NaCl, and 0.005% surfactant P20 supplied by the manufacturer) 
supplemented with 1% BSA. Approximately 2,000–3,000 RU of α-Gal-
Cer–loaded human and mouse CD1d was immobilized onto streptavidin-
coupled sensor chip (BiaCore). Corresponding levels of “unloaded” CD1d 
were also immobilized to act as controls. Equilibrium affi   nity was deter-
mined by injecting increasing concentrations of NKT TCR over all fl  ow 
cells at 5 μl/min for 3 min. The fi  nal response was calculated by subtracting 
the response of the “unloaded” CD1d surface from the α-GalCer CD1d 
surface. BIAevaluation version 3.1 (Biacore AB) was used to fi  t the equilib-
rium data.
CD1d/𝗂-GalCer tetramer inhibition assay and fl  ow  cytometry. 
Anti-CD3–FITC (clone 145-2C11) was purchased from BD Biosciences. 
Fc-receptor block (anti-CD16/CD32, clone 2.4G2) was added to all stain-
ing cocktails. Mouse CD1d tetramer loaded with α-GalCer was produced 
as described previously (70). CD1d/α-GalCer tetramer was incubated with 
serially diluted (twofold dilutions from 500 μg/ml to 4 μg/ml) soluble hu-
man NKT cell TCR or an irrelevant TCR (LC13) control. Thymic cell sus-
pensions were made by gently grinding the organ between the frosted ends 
of glass microscope slides in ice-cold PBS containing 2% FCS (FACS buff  er). 
Cell suspensions were passed through 100 μm mesh before antibody stain-
ing. Equivalent inhibition of staining of thymocytes with CD1d/α-GalCer 
tetramers was observed with NKT12, NKT15, NKT18, and NKT15‘AAA’ 
TCRs, and inhibition with these NKT TCRs was diminished equally upon 
dilution. Thymocytes were stained with anti-CD3 mAb, washed with FACS 
buff  er, and stained with the CD1d/α-GalCer tetramer–TCR mixtures. Cells 
were washed with FACS buff  er to remove any unbound CD1d/α-GalCer 
tetramer and analyzed by fl   ow cytometry using a FACScalibur (Becton 
Dickinson) and analyzed using CELLQuest software (Becton Dickinson).
Modelling of the NKT TCR–CD1d–𝗂-GalCer complex. The docking 
of NKT12 onto hCD1d was approximated in the following way. The MHC 
of each of the MHC–peptide–TCR complex structures available in the PDB 
was aligned onto the CD1d antigen-binding domain (residues 61–86 and 
139–171). The TCRs from each of the complexes were examined for clashes 
with the helices of hCD1d and the α-GalCer. The TCR with the best fi  t 
over CD1d/α-GalCer was LC13 (PDB code: 1MI5) and so the Cα domain 
of LC13 was used to superpose NKT12 in the fi  nal  CD1d–α-GalCer–
NKT12 model. NKT12 was adjusted manually using the program “O” to 
promote a better fi  t for our proposed model.
Online supplemental material. Supplemental Materials and methods for 
cDNA cloning of NKT TCRs and CD1d are provided. Table S1 provides 
contacts at the Vα–Vβ interface of NKT12 and the genetic origin of TCR 
residues. Table S2 describes the Phi psi torsion angles of CDR1 and CDR2 
in NKT12. Table S3 describes the dissociation constants of natural and mu-
tated NKT TCRs with CD1d/α-GalCer. Table S4 gives the amino acid 
  sequences of CDR3β residues in natural and mutated NKT TCRs. Fig. S1 
models the Ag-binding cavity of the NKT TCR to demonstrate how this 
can accommodate the galactose head group of α-GalCer. Fig. S2 shows the 
SPR sensorgrams and affi   nity estimations of NKT12 binding to immobilized 
hCD1d-GalCer and mCD1d-GalCer. Online supplemental material is avail-
able at http://www.jem.org/cgi/content/full/jem.20051777/DC1.
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